First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Yifan Zhai(Unknown), Hengbang Wang, Yan Yin(Suzhou Thermal Engineering Research Institute), Mary C. Collins(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Drew Rasco(Texas Oncology), Ping Min(Suzhou Thermal Engineering Research Institute), Lichuang Men(Suzhou Thermal Engineering Research Institute), Tommy Fu, Dajun Yang(Ascendis Pharma (Denmark)), Eric Liang(Vifor Pharma (United States))
Cited by 24
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606